Archive: April 2022

Immunotherapy for Ovarian Cancer

Abstract: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with poor survival rates among patients who have advanced disease despite recent significant advances in […]

Prostate-Specific Membrane Antigen–Targeted Theranostics: Past, Present, and Future Approaches

Abstract: Although prostate cancer is the type of cancer most commonly survived by men in the United States, it remains the second most common cause of […]

Is Neoadjuvant Therapy Ready for Prime Time in Melanoma?

H&O  What is the rationale for using neoadjuvant therapy in solid-organ cancers?  MR  Multimodality therapy has been shown to improve treatment outcomes vs surgery alone in […]

The Emerging Role of Pirtobrutinib in Chronic Lymphocytic Leukemia

H&O  How has the advent of Bruton tyrosine kinase (BTK) inhibitors impacted the treatment of patients with chronic lymphocytic leukemia (CLL)?  NL  The advent of BTK […]

COVID-19 Vaccine Development

My letter in the February 2022 issue of Clinical Advances in Hematology & Oncology called for Dr Anthony Fauci to address inherent deficiencies in our national […]

Should Secondary Cytoreduction Be Used in Recurrent Ovarian Cancer?

H&O  What is the rationale behind secondary cytoreduction in recurrent ovarian cancer?  SNW  The goal of upfront optimal cytoreduction is to improve outcomes—both progression-free survival (PFS) […]

Insights Into the Management of Patients With Primary Central Nervous System Lymphoma

H&O What is the definition of primary central nervous system (CNS) lymphoma ? CF  Primary CNS lymphoma is referred to as primary diffuse large B-cell lymphoma […]

Back to Archive